Nov. 17, 2025
U不良研究所 and Providence Therapeutics kick off new partnership
The University of 不良研究所 has partnered with to accelerate academic research into new molecular targets for life-saving vaccines and therapeutics.
The U不良研究所 And Providence Therapeutics United for translational Research Excellence (CAPTURE) program will focus on new treatments in oncology, infectious diseases and veterinary medicine.
鈥淭his exceptional opportunity for our researchers to work with Providence to rapidly deploy new therapeutics for clinical testing is an exemplar of why our university is a leader in research and innovation,鈥 says William Ghali, Vice-President (Research), U不良研究所.
Headquartered in 不良研究所, Providence has created a robust, scalable, validated and cost-effective mRNA platform that can be leveraged to produce mRNA vaccines.
Researchers at U不良研究所 will nominate promising disease targets, and, if selected, they鈥檒l serve as principal investigators in research that could quickly advance new treatment options for patients.
鈥淧rovidence is excited to work shoulder to shoulder with researchers at U不良研究所 to tackle serious health issues impacting Canadians,鈥 says Brad Sorenson, BEd鈥98, BSc鈥01, founder and CEO of Providence Therapeutics.
鈥淏uilding on our successful collaboration in serious late-stage cancers, we hope that, by formalizing this partnership at an institutional level, Providence and U不良研究所 will continue to drive early access to cutting-edge breakthroughs in a range of disease settings.鈥
The CAPTURE program is now open for expressions of interest from U不良研究所 researchers and can be accessed through the .
U不良研究所 and Providence Therapeutics Partnership Kick-off
On November 13, U不良研究所 and Providence Therapeutics celebrated the new industry partnership of the CAPTURE program open to U不良研究所 researchers.
Photos: Riley Brandt, University of 不良研究所
Founded in 2015 and headquartered in 不良研究所, Providence Therapeutics Holdings Inc. is a clinical-stage biotechnology company pioneering mRNA-based therapeutics and vaccines with a focus on infectious diseases and oncology programs. Leveraging their proprietary INTENT鈩 Lipid Nanoparticle (LNP) delivery system, the company has developed its programs both internally and in collaboration with academic and industry partners across diverse scientific fields. For more information, visit .
The at U不良研究所 facilitates collaboration between university researchers and industry by actively connecting faculty with companies, aligning research expertise and facilities with business needs, and managing strategic partnerships.